• Tanja E Hamm-Faber, VissersKris C PKCPDepartment of Anesthesiology, Pain, and Palliative Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Joke S Kalkman, Frank G A M van Haren, Hans J A Aukes, Yvonne Engels, and Dylan J H A Henssen.
• Department of Pain Medicine, Albert Schweitzer Hospital, Zwijndrecht, The Netherlands. Electronic address: tefaber01@gmail.com.
• Neuromodulation. 2024 Jan 1; 27 (1): 596959-69.

ObjectivesPsychologic screening is often included as a mandatory component of evaluation of the impact of psychopathology disorders on the predicted outcome of spinal cord stimulation (SCS) for patients with chronic pain due to persistent spinal pain syndrome type 2 (PSPS type 2). The conclusion of such screenings can influence the decision to offer SCS therapy to a patient. However, evidence on the impact of psychopathology on SCS outcomes is still scarce.Materials And MethodsTo address this knowledge gap, we systematically reviewed the literature from 2009 to 2021 to explore the correlation between the presence of a psychopathological disorder and the predicted outcome of SCS in patients with PSPS type 2. The literature search was conducted using various online data bases with "failed back surgery syndrome," "psychopathology," and "spinal cord stimulation" used as essential keywords. The identified studies were organized in a Rayyan AI data base, and the quality was analyzed with the Critical Appraisal Skills Program tool.ResultsOur search generated the identification of 468 original articles, of which two prospective and four retrospective studies met our inclusion criteria. These studies reported pain relief, a reduction of symptoms of anxiety and depression, and an improvement in rumination on the Pain Catastrophizing Scale in patients with PSPS type 2 after SCS therapy. The studies also found contradictory outcomes measured using the Oswestry Disability Index, and in terms of the impact of psychopathological disorder on the clinical outcome and revision rate of the SCS system.ConclusionIn this systematic review, we found no convincing evidence that the presence of a psychopathological disorder affects the predicted outcome of SCS therapy in patients with PSPS type 2.Copyright © 2023 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.

11 keywords...

hide…